Upload
others
View
4
Download
0
Embed Size (px)
Citation preview
152
BIBLIOGRAPHY
1. Aires KA, Cianciarullo AM, Carneiro SM, Villa LL, Boccardo E,
Perez-Martinez G. Production of human papillomavirus type 16 L1
virus-like particles by recombinant Lactobacillus casei cells. Appl.
Environ. Microbiol. 72, 2006: 745–752.
2. Al Saleh, W., Giannini, S.L., Jacobs, N., Moutschen, M., Doyen, J.,
Boniver, J., and Delvenne, P. Correlation of T-helper secretory
differentiation and types of antigen-presenting cells in squamous
intraepithelial lesions of the uterine cervix. J Pathol. 184, 1998:
283–290.
3. Alexander, M., Salgaller, M. L., Celis, E., Sette, A., Barnes, W. A.,
Rosenberg, S. A., and Steller, M. A. Generation of tumor-specific
cytolytic T lymphocytes from peripheral blood of cervical cancer
patients by in vitro stimulation with a synthetic human
papillomavirus type 16 E7 epitope. Am J Obstet Gynecol. 175,
1996: 1586-1593.
4. Amin, A.A., Titolo, S., Pelletier, A., Fink, D., Cordingley, M.G. &
Archambault, J. Identification of domains of the HPV11 E1 protein
required for DNA replication in vitro. Virology. 272, 2000: 137–150.
153
5. Amtmann E, Müller H, Sauer G. Equine connective tissue tumors
contain unintegrated bovine papilloma virus DNA. J Virol. 35,
1980: 962-964.
6. Apple, R.J., Erlich, H.A., Klitz, W., Manos, M.M., Becker, T.M., and
Wheeler, C.M. HLA DR-DQ associations with cervical carcinoma
show papillomavirus-type specificity. Nat Genet. 6, 1994: 157–162.
7. Apt D, Watts RM, Suske G, Bernard HU. High Sp1/Sp3 ratios in
epithelial cells during epithelial differentiation and cellular
transformation correlate with the activation of the HPV-16
promoter. Virology. 224, 1996: 281-91.
8. Arany, I., Rady, P., and Tyring, S.K. Alterations in
cytokine/antioncogene expression in skin lesions caused by “low-
risk” types of human papillomaviruses. Viral Immunol. 6, 1993:
255–265.
9. Arbyn M, Dillner J. Review of current knowledge on HPV
vaccination: An Appendix to the European Guidelines for Quality
Assurance in Cervical Cancer Screening. J. Clin. Viro. 38, 2007:
189–197.
154
10. Ault KA Effect of prophylactic human papillomavirus L1 virus-like-
particle vaccine on risk of cervical intraepithelial neoplasia grade 2,
grade 3, and adenocarcinoma in situ: a combined analysis of four
randomized clinical trials. Lancet. 369, 2007: 1861–1868.
11. Baker, T.S., Newcomb, W.W., Olson, N.H., Cowsert, L.M., Olson,
C., and Brown, J.C. Structures of bovine and human
papillomaviruses: analysis by cryoelectron microscopy and three-
dimensional image reconstruction. Biophys J. 60, 1991: 1445–
1456.
12. Band, V., Zajchowski, D., Kulesa, V. & Sager, R. Human papilloma
virus DNAs immortalize normal human mammary epithelial cells
and reduce their growth factor requirements. Proc natl Acad Sci USA.
87, 1990: 463–467.
13. Banks, L., Matlashewski, G., Pim, D., Churcher, M., Roberts, C.,
and Crawford, L. Expression of human papillomavirus type 6 and
type 16 capsid proteins in bacteria and their antigenic
characterization. J Gen Virol. 68, 1987: 3081-3089.
14. Basu P, Chowdhury D. Cervical cancer screening& HPV
vaccination: a comprehensive approach to cervical cancer control.
Ind J Med Res. 130, 2009: 241-246.
155
15. Baud, D., Ponci, F., Bobst, M., De Grandi, P., and Nardelli-
Haefliger, D. Improved efficiency of a Salmonella-based vaccine
against human papillomavirus type 16 virus-like particles achieved
by using a codon-optimized version of L1. J Virol. 78, 2004: 12901–
12909.
16. Bazan SB, de Alencar Muniz Chaves A, Aires KA, Cianciarullo AM,
Garcea RL, Ho PL. Expression and characterization of HPV-16 L1
capsid protein in Pichia pastoris. Arch Virol. 154, 2009: 1609-1617.
17. Bernard HU, Burk RD, Chen Z, van Doorslaer K, Hausen H, de
Villiers EM. Classification of papillomaviruses (PVs) based on 189
PV types and proposal of taxonomic amendments. Virology. 401,
2010: 70–79.
18. Bharadwaja M, Hussain S, Nasare V, Das BC. HPV & HPV
vaccination: Issues in developing countries. Ind J Med Res. 130,
2009: 327-333.
19. Bimelt S, Sonnewald U, Galmbachar P, Willmitzer L, Muller M.
Production of human papillomaviruses type 16 virus-like particles
in transgenic plants. J Virol . 77, 2003: 9211-9220.
156
20. Borzacchiello, G., Ambrosio, V., Roperto, S., Poggiali, F.,
Tsirimonakis, E., Venuti, A., Campo, M.S. & Roperto, F. Bovine
papillomavirus type 4 in oesophageal papillomas of cattle from the
south of Italy. J comp Pathol. 128, 2003b: 203–206.
21. Borzacchiello G, Russo V, Spoleto C, Roperto S, Balcos L, Rizzo C,
Venuti A, Roperto F. Bovine papillomavirus type-2 DNA and
expression of E5 and E7 oncoproteins in vascular tumours of the
urinary bladder in cattle. Cancer Lett. 18; 250, 2007: 82-91.
22. Bosch, F.X., Manos, M.M., Munoz, N., Sherman, M., Jansen, A.M.,
Peto, J., Schiffman, M.H.,Moreno, V., Kurman, R. & Shah, K.V. for
the International Biological Study on Cervical Cancer (IBSCC) Study
Group Prevalence of human papillomavirus in cervical cancer: A
worldwide perspective. J. natl Cancer Inst. 87, 1995: 796–802.
23. Bosch FX, Munoz N: The viral etiology of cervical cancer. Virus Res.
89, 2002:183-190.
24. Bosch, F. X., Lorincz, A., Munoz, N., Meijer, C. J., and Shah, K. V.
The causal relation between human papillomavirus and cervical
cancer. J Clin Pathol. 55, 2002: 244-265.
157
25. Bosch FX. Epidemiology of human papillomavirus infections: new
options for cervical cancer prevention. Salud Publica Mex. 45 (Suppl
3), 2003: S326-39.
26. Bosch FX, de Sanjosé S. Human papillomavirus and cervical
cancer--burden and assessment of causality. J Natl Cancer Inst
Monogr. 31, 2003: 3-13.
27. Boshart, M., Gissmann, L., Ikenberg, H., Kleinheinz, A., Scheurlen,
W., and zur, H. H. A new type of papillomavirus DNA, its presence
in genital cancer biopsies and in cell lines derived from cervical
cancer. EMBO J. 3, 1984: 1151-1157.
28. Boursnell, M. E., Rutherford, E., Hickling, J. K., Rollinson, E. A.,
Munro, A. J., Rolley, N., McLean, C. S., Borysiewicz, L. K., Vousden,
K., and Inglis, S. C. Construction and characterisation of a
recombinant vaccinia virus expressing human papillomavirus
proteins for immunotherapy of cervical cancer. Vaccine 14, 1996:
1485-1494.
29. Bouvard, V., Matlashewski, G., Gu, Z.-M., Storey, A. & Banks, L.
The human papillomavirus type 16 E5 gene cooperates with the E7
gene to stimulate proliferation of primary cells and increases viral
gene expression. Virology, 203, 1994b: 73–80.
158
30. Breitburd, F., Kirnbauer, R., Hubbert, N.L., Nonnenmacher, B.,
Trin-Dinh- Desmarquet, C., Orth, G., Schiller, J.T., and Lowy, D.R.
Immunization with virus-like particles from cottontail rabbit
papillomavirus (CRPV) can protect against experimental CRPV
infection. J Virol. 69, 1995: 3959–3963.
31. Broker, T.R., and Botchan, M.Papillomaviruses: Retrospectives and
prospectives. Cancer Cells. 4, 1986: 17–36.
32. Burchell AN, Winer RL, de Sanjosé S, Franco EL. Epidemiology and
transmission dynamics of genital HPV infection. Vaccine. 24 Suppl
3:S3, 2006: 52-61.
33. Buck CB, Pastrana DV, Lowy DR, Schiller JT. Generation of HPV
pseudovirions using transfection and their use in neutralization
assays. Methods Mol Med. 119, 2005: 445-462.
34. Burd EM. Human papillomavirus and cervical cancer. Clin
Microbiol Rev. 16, 2003: 1-17.
35. Campo, M.S., Moar, M.H., Jarrett, W.F.H. & Laird, H.M.A new
papillomavirus associated with alimentary cancer in cattle. Nature.
286, 1980: 180–182.
159
36. Campo, M.S. Animal models of papillomavirus pathogenesis. Virus
Res. 89, 2002: 249–261.
37. Carroll, M. W. and Moss, B. Poxviruses as expression vectors. Curr
Opin Biotechnol. 8, 1997: 573-577.
38. Carstens CP.Use of tRNA-supplemented host strains for expression
of heterologous genes in E. coli. Methods Mol Biol. 205, 2003: 225–
233.
39. Carter, J. J., Koutsky, L. A., Hughes, J. P., Lee, S. K., Kuypers, J.,
Kiviat, N., and Galloway, D. A. Comparison of human
papillomavirus types 16, 18, and 6 capsid antibody responses
following incident infection. J Infect Dis. 181, 2000: 1911-1919.
40. Casini, G.L., Graham, D., Heine, D., Garcea, R.L., and Wu, D.T. In
vitro papillomavirus capsid assembly analyzed by light scattering.
Virology. 325, 2004: 320–327.
41. Chambers MA, Stacey SN, Arrand JR, Stanley MA. Delayed-type
hypersensitivity response to human papillomavirus type 16 E6
protein in a mouse model. J Gen Virol. 75, 1994:165-9.
160
42. Chan, S. Y., Delius, H., Halpern, A. L., and Bernard, H. U. Analysis
of genomic sequencesof 95 papillomavirus types: uniting typing,
phylogeny, and taxonomy. J Virol. 69, 3074-3083.
43. Cheng, S., Schmidt-Grimminger, D.C., Murant, T., Broker, T.R.,
and Chow, L.T. Differentiation-dependent up-regulation of the
human papillomavirus E7 gene reactivates cellular DNA replication
in suprabasal differentiated keratinocytes. Genes Dev. 9, 1995:
2335–2349.
44. Chen, X.S., Garcea, R.L., Goldberg, I., Casini, G. & Harrison, S.C.
Structure of small virus like particles assembled from the L1
protein of human papillomavirus 16. Mol Cell. 5, 2000: 557–567.
45. Chen, X. S., Casini, G., Harrison, S. C., and Garcea, R. L.
Papillomavirus capsid protein expression in Escherichia coli:
purification and assembly of HPV11 and HPV16 L1. J Mol Biol. 307,
2001:173-182.
46. Chiang, C. M., Ustav, M., Stenlund, A., Ho, T. F., Broker, T. R.,
and Chow, L. T. Viral E1 and E2 proteins support replication of
homologous and heterologous papillomaviral origins. Proc Natl Acad
Sci. 89, 1992: 5799-5803.
161
47. Christensen, N. D. and Kreider, J. W. Antibody-mediated
neutralization in vivo of infectious papillomaviruses. J Virol. 64,
1990: 3151-3156.
48. Christensen, N. D., Hopfl, R., DiAngelo, S. L., Cladel, N. M.,
Patrick, S. D., Welsh, P. A., Budgeon, L. R., Reed, C. A., and
Kreider, J. W. Assembled baculovirus-expressed human
papillomavirus type 11 L1 capsid protein virus-like particles are
recognized by neutralizing monoclonal antibodies and induce high
titres of neutralizing antibodies. J Gen Virol. 75, 1994a: 2271-2276.
49. Christensen, N. D., Dillner, J., Eklund, C., Carter, J. J., Wipf, G.
C., Reed, C. A., Cladel, N. M., and Galloway, D. A. Surface
conformational and linear epitopes on HPV-16 and HPV-18 L1
virus-like particles as defined by monoclonal antibodies. Virology.
223, 1996a: 174-184.
50. Christensen, N.D., Cladel, N.M., Reed, C.A. & Han, R. Rabbit oral
papillomavirus complete genome sequence and immunity following
genital infection. Virology. 269, 2000: 451–461.
51. Chu, N. R., Wu, H. B., Wu, T., Boux, L. J., Siegel, M. I., and
Mizzen, L. A. Immunotherapy of a human papillomavirus (HPV) type
16 E7-expressing tumour by administration of fusion protein
162
comprising Mycobacterium bovis bacille Calmette-Guerin (BCG)
hsp65 and HPV16 E7. Clin Exp Immunol. 121, 2000: 216-225.
52. Coleman, N., Birley, H.D., Renton, A.M., Hanna, N.F., Ryait, B.K.,
Byrne, M., Taylor- Robinson, D., and Stanley, M.A. Immunological
events in regressing genital warts. Am J Clin Pathol. 102, 1994:
768–774.
53. Combita, A. L., Touze, A., Bousarghin, L., Christensen, N. D., and
Coursaget, P. Identification of two cross-neutralizing linear epitopes
within the L1 major capsid protein of human papillomaviruses. J
Virol. 76, 2002: 6480-6486.
54. Cook CJ, Joyce GJ, George AH, Schultz DL, Hurni MW, Jansen
UK, Hepler WR, Charlotte IP, Lowe SR, Keller MP, Lehman DE.
Purification of Virus-like Particles of Recombinant Human
papillomavirus Type 11 Major Capsid Protein L1fr`om
Saccharomyces cerevisiae. Prot Expr Pur. 17, 1999: 477–484.
55. Cregg JM, Cereghino JI, Shi J, Higgins DR. Recombinant protein
expression in Pichia pastoris. Mol Biotechnol. 16, 2000: 23-52.
56. Crotty, S., Miller, C. J., Lohman, B. L., Neagu, M. R., Compton, L.,
Lu, D., Lu, F. X., Fritts, L., Lifson, J. D., and Andino, R. Protection
163
against simian immunodeficiency virus vaginal challenge by using
Sabin poliovirus vectors. J Virol. 75, 2001: 7435-7452.
57. Crusius, K., Auvinen, E. & Alonso, A. Enhancement of EGF- and
PMA-mediated MAP kinase activation in cells expressing the human
papillomavirus type 16 E5 protein. Oncogene. 15, 1997: 1437–
1444.
58. Crusius, K., Auvinen, E., Steuer, B., Gaissert, H. & Alonso, A. The
human papillomavirus type 16 E5-protein modulates ligand-
dependent activation of the EGF receptor family in the human
epithelial cell line HaCaT. Exp Cell Res. 241, 1998: 76–83.
59. Cumberbatch, M. and Kimber, I. Dermal tumour necrosis factor-
alpha induces dendritic cell migration to draining lymph nodes, and
possibly provides one stimulus for Langerhans’ cell migration.
Immunology. 75, 1992: 257–263.
60. Cuzick J, Arbyn M, Sankaranarayanan R, Tsu V, Ronco G,
Mayrand MH, Dillner J, Meijer CJ. Overview of human
papillomavirus-based and other novel options for cervical cancer
screening in developed and developing countries. Vaccine. 26, Suppl
10, 2008: K29-41.
164
61. Danos, O., Giri, I., Thierry, F., and Yaniv, M. Papillomavirus
genomes: sequences and consequences. J Invest Dermatol. 83,
Suppl 1, 1984: S7–11.
62. Davidson, E. J., Brown, M. D., Burt, D. J., Parish, J. L., Gaston,
K., Kitchener, H. C., Stacey, S. N., and Stern, P. L. Human T cell
responses to HPV 16 E2 generated with monocyte derived dendritic
cells. Int J Cancer. 94, 2001: 807-812.
63. Da Silva, D.M., Pastrana, D.V., Schiller, J.T., and Kast, W.M. Effect
of preexisting neutralizing antibodies on the anti-tumor immune
response induced by chimeric human papillomavirus virus-like
particle vaccines. Virology. 290, 2001: 350–360.
64. Das BC, Hussain S, Nasare V, Bharadwaj M. Prospects and
prejudices of human papillomavirus vaccines in India. Vaccine. 26,
2008: 2669-2679.
65. Day, P. M., Roden, R. B., Lowy, D. R., and Schiller, J. T. The
papillomavirus minor capsid protein, L2, induces localization of the
major capsid protein, L1, and the viral transcription/replication
protein, E2, to PML oncogenic domains. J Virol. 72, 1998: 142-150.
66. De Bruijn, M.L.H., Greenstone, H.L., Vermeulen, H., Melief, C.J.M.,
Lowy, D.R., Schiller, J.T., and Kast, W.M. L1-specific protection
165
from tumor challenge elicited by HPV16 virus-like particles.
Virology. 250, 1998: 371–376.
67. del Mar Pena, L.M., and Laimins, L.A. Differentiation-dependent
chromatin rearrangement coincides with activation of human
papillomavirus type 31 late gene expression. J Virol. 75, 2001:
10005–10013.
68. Deng, S.-J., Pearce, K.H., Dixon, E.P., Hartley, K.A., Stanley, T.B.,
Lobe, D.C., Garvey, E.P., Kost, T.A., Petty, R.L., Rocque, W.J.,
Alexander, K.A. & Underwood, M.R. Identification of peptides that
inhibit the DNA binding, trans-activator, and DNA replication
functions of the human papillomavirus type 11 E2 protein. J Virol.
78, 2004: 2637–2641.
69. De Villier EM, Fauquet C, Broker TR, Bernard HU, zur Hausen
H.Classification of papillomaviruses. Virology. 324, 2004: 17–27
70. Desaintes, C. & Demeret, C. Control of papillomavirus DNA
replication and transcription. Semin Cancer Biol. 7, 1996: 339–347.
71. Desaintes, C., Demeret, C., Goyat, S., Yaniv, M., and Thierry, F.
Expression of the papillomavirus E2 protein in HeLa cells leads to
apoptosis. EMBO J. 16, 1997: 504-514.
166
72. Dillner, J., Lehtinen, M., Bjorge, T., Luostarinen, T., Youngman, L.,
Jellum, E., Koskela, P., Gislefoss, R.E., Hallmans, G., Paavonen, J.,
Sapp, M., Schiller, J.T., Hakulinen, T., Thoresen, S., and Hakama,
M. Prospective seroepidemiologic study of human papillomavirus
infection as a risk factor for invasive cervical cancer. J Natl Cancer
Inst. 89, 1997: 1293–1299.
73. Doorbar, J. The papillomavirus life cycle. J Clin Virol. 32 Suppl 1,
2005: S7–S15.
74. Favre M, Majewski S, De Jesus N, Malejczyk M, Orth G, Jablonska
S. A possible vertical transmission of human papillomavirus
genotypes associated with epidermodysplasia verruciformis. J Invest
Dermatol. 111, 1998: 333-336.
75. Fehrmann, F. & Laimins, L.A. Human papillomaviruses: Targeting
differentiating epithelial cells for malignant transformation.
Oncogene. 22, 2003: 5201–5207.
76. Ferlay, J., Bray, F., Pisani, P., and Parkin, D.M. GLOBOCAN 2002:
Cancer Incidence, Mortality and Prevalence Worldwide. Lyon: IARC
Press, 2004.
77. Fernando, G. J., Murray, B., Zhou, J., and Frazer, I. H.
Expression, purification and immunological characterization of the
167
transforming protein E7, from cervical cancerassociated human
papillomavirus type 16. Clin Exp Immunol. 115, 1999: 397-403.
78. Fernández-San Millán A, Ortigosa SM, Hervás-Stubbs S, Corral-
Martínez P, Seguí-Simarro JM, Gaétan J, Coursaget P, Veramendi
J. Human papillomavirus L1 protein expressed in tobacco
chloroplasts self-assembles into virus-like particles that are highly
immunogenic. Plant Biotechnol J. 6, 2008: 427-441.
79. Flores, E.R., Allen-Hoffmann, B.L., Lee, D., Sattler, C.A., and
Lambert, P.F. Establishment of the human papillomavirus type 16
(HPV-16) life cycle in an immortalized human foreskin keratinocyte
cell line. Virology. 262, 1999: 344–354.
80. Flores, E.R., Allen-Hoffmann, B.L., Lee, D., and Lambert, P.F. The
human papillomavirus type 16 E7 oncogene is required for the
productive stage of the viral life cycle. J Virol. 74, 2000: 6622–6631.
81. Florin, L., Sapp, C., Streeck, R. E., and Sapp, M. Assembly and
Translocation of Papillomavirus Capsid Proteins. J Virol. 76, 2002:
10009-10014.
82. Fisher, S.G., Benitez-Bribiesca, L., Nindl, I., Stockfleth, E., Muller,
M., Wolf, H., Perez-Garcia, F., Guzman-Gaona, J., Gutierrez-
Delgado, F., Irvin, W., and Gissmann, L. The association of human
168
papillomavirus type 16 E6 and E7 antibodies with stage of cervical
cancer. Gynecol Oncol. 61, 1996: 73–78.
83. Franceschi S, Rajkumar T, Vaccarella S, Gajalakshmi V, Sharmila
A, Snijders PJ, et al. Human papillomavirus and risk factors for
cervical cancer in Chennai, in India: a case control study. Int J
Cancer. 107, 2003: 127-133.
84. Frattini, M.G. & Laimins, L.A. Binding of the human
papillomavirus E1 origin-recognition protein is regulated through
complex formation with the E2 enhancer-binding protein. Proc Natl
Acad Sci USA. 91, 1994: 12398–12402.
85. Frattini, M.G., Lim, H.B., and Laimins, L.A. In vitro synthesis of
oncogenic human papillomaviruses requires episomal genomes for
differentiation-dependent late expression. Proc Natl Acad Sci USA.
93, 1996: 3062–3067.
86. Gambhira, R., S. Jagu, B. Karanam, P. E. Gravitt, T. D. Culp, N. D.
Christensen and R. B. S. Roden. Protection of rabbits against
challenge with rabbit papillomaviruses by immunization with the N
terminus of human papillomavirus type 16 minor capsid antigen
L2. J Virol. 81, 2007: 11585–11592.
169
87. Gao, L., Chain, B., Sinclair, C., Crawford, L., Zhou, J., Morris, J.,
Zhu, X., and Stauss, H. Immune response to human papillomavirus
type 16 E6 gene in a live vaccinia vector. J Gen Virol. 75, 1994: 157-
164.
88. Garland SM, Hernandez-Avila M, Wheeler CM, Perez G, Harper
DM, Leodolter S, Tang GW, Ferris DG, Steben M, Bryan J, Taddeo
FJ, Railkar R, Esser MT, Sings HL, Nelson M, Boslego J, Sattler C,
Barr E, Koutsky LA; Females United to Unilaterally Reduce
Endo/Ectocervical Disease (FUTURE) I Investigators. Quadrivalent
vaccine against human papillomavirus to prevent anogenital
diseases. N Engl J Med. 356, 2007: 1928-1943.
89. GAVI Alliance Progress Report (GAVI Alliance, Geneva, 2007).
http://www.gavialliance.org/resources/2007GAVIreport.pdf.
90. Giroglou, T., Sapp, M., Lane, C., Fligge, C., Christensen, N. D.,
Streeck, R. E., and Rose, R. C. Immunological analyses of human
papillomavirus capsids. Vaccine. 19, 2001: 1783-1793.
91. Glas, R., Franksson, L., Une, C., Eloranta, M.L., Ohlen, C., Orn,
A., and Karre, K. Recruitment and activation of natural killer (NK)
cells in vivo determined by the target cell phenotype. An adaptive
170
component of NK cell-mediated responses. J Exp Med. 191, 2000:
129–138.
92. Grassmann, K., Rapp, B., Maschek, H., Petry, K.U., and Iftner, T.
Identification of a differentiation-inducible promoter in the E7 open
reading frame of human papillomavirus type 16 (HPV-16) in raft
cultures of a new cell line containing high copy numbers of
episomal HPV-16 DNA. J Virol. 70, 1996: 2339–2349.
93. Gravitt, P.E., Peyton, C.L., Apple, R.J. & Wheeler, C.M. Genotyping
of 27 human papillomavirus types by using L1 consensus PCR
products by a single hybridization, reverse line blot detection
method. J clin Microbiol. 36, 1998: 3020–3027.
94. Greenstone, H. L., Nieland, J. D., de Visser, K. E., De Bruijn, M. L.,
Kirnbauer, R., Roden, R. B., Lowy, D. R., Kast, W. M., and Schiller,
J. T. Chimeric papillomavirus virus-like particles elicit antitumor
immunity against the E7 oncoprotein in an HPV16 tumor model.
Proc Natl Acad Sci. 95, 1998: 1800-1805.
95. Gustafsson C, Govindarajan S, Minshull J . Codon bias and
heterologous protein expression. Trends Biotechnol. 22, 2004: 346–
353.
171
96. Hagenson MJ. Production of recombinant proteins in the
methylotrophic yeast Pichia pastoris. Bioprocess Technol. 12, 1991:
193-212.
97. Hagensee, M. E., Yaegashi, N., and Galloway, D. A. Self-assembly
of human papillomavirus type 1 capsids by expression of the L1
protein alone or by coexpression of the L1 and L2 capsid proteins. J
Virol. 67, 1993: 315-322.
98. Hagensee, M.E., Olson, N.H., Baker, T.S. & Galloway, D.A. Three-
dimensional structure of vaccinia virus-produced human
papillomavirus type 1 capsids. J Virol. 68, 1994: 4503–4505.
99. Halbert, C.L., Demers, G.W., and Galloway, D.A. The E6 and E7
genes of human papillomavirus type 6 have weak immortalizing
activity in human epithelial cells. J Virol. 66, 1992: 2125–2134.
100. Hariharan, K., Braslawsky, G., Barnett, R. S., Berquist, L.
G., Huynh, T., Hanna, N., and Black, A. Tumor regression in mice
following vaccination with human papillomavirus E7 recombinant
protein in PROVAX. Int. J Oncol. 12, 1998: 1229-1235.
101. Harper, D.M., Franco, E.L., Wheeler, C., Ferris, D.G.,
Jenkins, D., Schuind, A., Zahaf, T., Innis, B., Naud, P., De
Carvalho, N.S., Roteli-Martins, C.M., Teixeira, J., Blatter, M.M.,
172
Korn, A.P., Quint, W., Dubin, G., and the GlaxoSmithKline HPV
Vaccine Study Group. Efficacy of a bivalent L1 virus-like particle
vaccine in prevention of infection with human papillomavirus types
16 and 18 in young women: A randomised controlled trial. Lancet.
364, 2004: 1757–1765.
102. Harper, D.M., Tamms, G.M., Yu, J., Lupinacci, L., Railkar, R.,
Taddeo, F.J., Jansen, K.U., Esser, M.T., Sings, H.L., Saah, A.J., and
Barr, E. Prophylactic quadrivalent human papillomavirus (types 6,
11, 16, and 18) L1 virus-like particle vaccine in young women: a
randomized double-blind placebo-controlled multicentre phase II
efficacy trial. Lancet Oncol. 6, 2005: 271–278.
103. Harper DM, Franco EL, Wheeler CM, Moscicki AB, Romanowski B,
Roteli-Martinus CM, Jenkins D, Schuind A, Clemens SAC, Dubin G.
Sustained efficacy up to 4.5 years of a bivalent L1 virus-like particle
vaccine against human papillomavirus types 16 and 18: follow up
from a randomized control trial. Lancet. 367, 2006: 1247-1255.
104. Heino, P., Zhou, J. & Lambert, P.F. Interaction of the
papillomavirus transcription/replication factor, E2, and the viral
capsid protein, L2. Virology, 276, 2000: 304–314.
173
105. Hildesheim A, Herrero R, Wacholder S et al. Effect of human
papillomavirus 16/18 L1 viruslike particle vaccine among young
women with preexisting infection: a randomized trial. JAMA. 298,
2007: 743–753.
106. Ho GY, Bierman R, Beardsley L, Chang CJ, Burk RD. Natural
history of cervovaginal papillomavirus infection in young women. N
Engl J Med. 338, 1998: 423-428.
107. Ho, G.Y., Studentsov, Y.Y., Bierman, R., and Burk, R.D. Natural
history of human papillomavirus type 16 virus-like particle
antibodies in young women. Cancer Epidemiol Biomarkers Prev. 13,
2004: 110–116.
108. Holmgren, S.C., Patterson, N.A., Ozbun, M.A. & Lambert, P.F. The
minor capsid protein L2 contributes to two steps in the human
papillomavirus type 31 life cycle. J Virol. 79, 2005: 3938–3948.
109. Howley, P. M. Papillomavirinae: The Viruses and Their Replication.
In "Fields Virology" (B. N. Fields, D. M. Knipe, and P. M. Howley,
Eds.), 1995: 2045-2076.
110. Howley, P.M., Lowy, D.R. Papillomaviruses and their replication. In
P.M. Howley (ed.): Virology, vol. 2. Philadelphia, PA: Lippincott/The
Williams & Wilkins Co. 2001: 2197–2229.
174
111. Hudson, J.B., Bedell, M.A., McCance, D.J., and Laimins, L.A.
Immortalization and altered differentiation of human keratinocytes in
vitro by the E6 and E7 open reading frames of human papillomavirus
type 18. J Virol. 64, 1990: 519–526.
112. Hughes, F.J. & Romanos, M.A. E1 protein of human
papillomavirus is a DNA helicase/ ATPase. Nucleic Acids Res. 21,
1993: 5817–5823.
113. Hummel, M., Hudson, J.B., and Laimins, L.A. Differentiation-
induced and constitutive transcription of human papillomavirus type
31b in cell lines containing viral episomes. J Virol. 66, 1992: 6070–
6080.
114. Hwang, E.-S., Nottoli, T. & DiMaio, D. The HPV16 E5 protein:
Expression, detection, and stable complex formation with
transmembrane proteins in COS cells. Virology. 211, 1995: 227–233.
115. Inglis S, Shaw A, Koenig S. HPV vaccines: commercial research &
development. Vaccine. 24 suppl 3, 2006: S99-S105.
116. Jarrett, W.F.H., Murphy, J., O’Neil, B.W. & Laird, H.M. Virus-
induced papillomas of the alimentary tract of cattle. Int J Cancer. 22,
1978b: 323–328.
175
117. Jarrett, W.F.H. The natural history of bovine papillomavirus
infections. In: Klein, G., ed., Advances in Viral Oncology, Vol. 5, New
York, Raven Press, 1985: 83–102
118. Jenison, S.A., Yu, X.P., Valentine, J.M., Koutsky, L.A.,
Christiansen, A.E., Beckmann, A.M., and Galloway, D.A. Evidence of
prevalent genital-type human papillomavirus infections in adults and
children. J Infect Dis. 162, 1990: 60–69.
119. Kabsch, K. & Alonso, A. The human papillomavirus type 16 E5
protein impairs TRAIL and FasL-mediated apoptosis in HaCaT cells
by different mechanisms. J Virol. 76, 2002: 12162–12172.
120. Kanda, T., Furuno, A., and Yoshiike, K. Humanpapillomavirustype
16 open reading frame E7 encodes a transforming gene for rat 3Y1
cells. J Virol. 62, 1988: 610–613.
121. Kashii, Y., Giorda, R., Herberman, R.B., Whiteside, T.L., and
Vujanovic, N.L. Constitutive expression and role of the TNF family
ligands in apoptotic killing of tumor cells by human NK cells. J
Immunol. 163, 1999: 5358–5366.
176
122. Kawana, K., Yoshikawa, H., Taketani, Y., Yoshiike, K., and Kanda,
T. Common neutralization epitope in minor capsid protein L2 of
human papillomavirus types 16 and 6. J Virol. 73, 1999: 6188-6190.
123. Kawana, Y., Kawana, K., Yoshikawa, H., T aketani, Y., Yoshiike, K.,
and Kanda, T. Human papillomavirus type 16 minor capsid protein
l2 N-terminal region containing a common neutralization epitope
binds to the cell surface and enters the cytoplasm. J Virol. 75, 2001b:
2331-2336.
124. Kawana, K., Yasugi, T., Kanda, T., Kino, N., Oda, K., Okada, S.,
Kawana, Y., Nei, T., Takada, T., Toyoshima, S., Tsuchiya, A., Kondo,
K., Yoshikawa, H., Tsutsumi, O. and Taketani, Y. Safety and
immunogenicity of a peptide containing the cross-neutralization
epitope of HPV16 L2 administered nasally in healthy volunteers.
Vaccine. 21, 2003: 4256–4260
125. Kell, B., Jewers, R. J., Cason, J., Pakarian, F., Kaye, J. N., and
Best, J. M. Detection of E5 oncoprotein in human papillomavirus
type 16-positive cervical scrapes using antibodies raised to synthetic
peptides. J Gen Virol. 75, 1994: 2451-2456.
177
126. Kennedy, I.M., Haddow, J.K. & Clements, J.B. A negative
regulatory element in the human papillomavirus type 16 genome acts
at the level of late mRNA stability. J Virol. 65, 1991: 2093–2097.
127. Kirnbauer, R., Booy, F., Cheng, N., Lowy, D. R., and Schiller, J. T.
Papillomavirus L1 major capsid protein self-assembles into virus-like
particles that are highly immunogenic. Proc Natl Acad Sci. 89, 1992:
12180-12184.
128. Kirnbauer, R., Taub, J., Greenstone, H., Roden, R., Durst, M.,
Gissmann, L., Lowy, D. R., and Schiller, J. T. Efficient self-assembly
of human papillomavirus type 16 L1 and L1-L2 into virus-like
particles. J Virol. 67, 1993: 6929-6936.
129. Knowles G, O'Neil BW, Campo MS. Phenotypical characterization
of lymphocytes infiltrating regressing papillomas. J Virol. 70, 1996:
8451-8.
130. Kochel, H.G., Sievert, K., Monazahian, M., Mittelstadt-Deterding,
A., Teichmann, A., and Thomssen, R. Antibodies to human
papillomavirus type-16 in human sera as revealed by the use of
prokaryotically expressed viral gene products. Virology. 182, 1991b:
644–654.
178
131. Koshiol J, Lindsay L, Pimenta JM, Poole C, Jenkins D, Smith JS.
Persistent human papillomavirus infection and cervical neoplasia: a
systematic review and meta-analyisis. Am J Epideminol. 168, 2008:
123-137.
132. Koutsky, L.A., Ault, K.A., Wheeler, C.M., Brown, D.R., Barr, E.,
Alvarez, F.B., Chiacchierini, L.M., and Jansen, K.U. A controlled trial
of a human papillomavirus type 16 vaccine. N Engl J Med. 347, 2002:
1645–1651.
133. Lacey C J. Therapy for genital human papillomavirus- related
disease. J Clin Virol. 32 Supple 1, 2005: S82-S90.
134. Lai YM, Yang FP, Pao CC. Human papillomavirus deoxyribonucleic
acid and ribonucleic acid in seminal plasma and sperm cells. Fertil
Steril. 65, 1996: 1026-1030.
135. Lambert, P.F. Papillomavirus DNA replication. J Virol. 65, 1991:
3417–3420.
136. Lamikanra, A., Pan, Z. K., Isaacs, S. N., Wu, T. C., and Paterson,
Y. Regression of established human papillomavirus type 16 (HPV-16)
immortalized tumors in vivo by vaccinia viruses expressing different
forms of HPV-16 E7 correlates with enhanced CD8(+) T-cell
responses that home to the tumor site. J Virol. 75, 2001: 9654-9664.
179
137. Leder C, Kleinschmidt JA, Wiethe C, Müller M. Enhancement of
capsid gene expression: preparing the human papillomavirus type 16
major structural gene L1 for DNA vaccination purposes. J Virol.
75(19), 2001: 9201-9.
138. Lenz, P., Day, P.M., Pang, Y.S., Frye, S.A., Jensen, P.N., Lowy,
D.R., and Schiller, J.T. Papillomavirus-like particles induce acute
activation of dendritic cells. J Immunol. 166, 2001: 5346–5355.
139. Lenzi P, Scotti N, Alagna F, Tornesello ML, Pompa A, Vitale A, De
Stradis A, Monti L, Grillo S, Buonaguro FM, Maliga P, Cardi T.
Translational fusion of chloroplast-expressed human papillomavirus
type 16 L1 capsid protein enhances antigen accumulation in
transplastomic tobacco. Transgenic Res. 17, 2008: 1091-102.
140. Li, M., Cripe, T. P., Estes, P. A., Lyon, M. K., Rose, R., and Garcea,
R. L. Expression of the Human Papillomavirus type 11 L1 capsid
protein in Escherichia coli: Characterization of protein domains
involved in DNA binding and capsid assembly. J Virol. 71, 1997:
2988-2995.
141. Liljeqvist, S. and Stahl, S. Production of recombinant subunit
vaccines: protein immunogens, live delivery systems and nucleic acid
vaccines. J Biotechnol. 73, 1999: 1-33.
180
142. Liu, M.A. DNA vaccines: A review. J Intern Med. 253, 2003: 402–
410.
143. Liu DW, Zhang Y, Yu XH, Jiang C, Chen Y, Wu Y, Jin Y. Assembly
and Immunogenicity of Human Papillomavirus Type 16 Major Capsid
Protein (HPV16 L1) in Pichia pastoris. Chem Res in Chinese Univ. 23,
2003: 200-203 (Seen as abstract only).
144. Longworth, M.S., and Laimins, L.A. The binding of histone
deacetylases and the integrity of zinc finger-like motifs of the E7
protein are essential for the life cycleof human papillomavirus type
31. J Virol. 78, 2004a: 3533–3541.
145. Lowy, D. R., Kirnbauer, R., and Schiller, J. T. Genital human
papillomavirus infection. Proc Natl Acad Sci. 91, 1994: 2436-2440.
146. Lowy D. The Papillomaviruses. (Robert L. Garcea, Daniel DiMaio
eds. Springer, 2007: 13-17.
147. Mach H, Volkin DB, Troutman RD, Wang B, Luo Z, Jansen KU, Shi
L. Disassembly and reassembly of yeast-derived recombinant human
papillomavirus virus-like particles (HPV VLPs). J Pharm Sci. 95(10),
2006: 2195-2206.
181
148. Mao C, Hughes JP, Kiviat N, Kuypers J, Lee SK, Adam DE,
Koutsky LA. Clinical findings among young women with genital
human papillomavirus infection. Am J Obstet Gynecol. 188, 2003:
677-684.
149. Martinez-Kinader, B., Lipford, G. B., Wagner, H., and Heeg, K.
Sensitization of MHC class I-restricted T cells to exogenous proteins:
evidence for an alternative class I-restricted antigen presentation
pathway. Immunology. 86, 1995: 287-295.
150. Martin, L.G., Demers, G.W., and Galloway, D.A. Disruption of the
G1/S transition in human papillomavirus type 16 E7-expressing
human cells is associated with altered regulation of cyclin E. J Virol.
72, 1998: 975–985.
151. Martina, B.M., Nina, M., Mia L., Lawrence B. and Helena, S.G.
Modification of Human Papillomavirus Minor Capsid Protein L2 by
Sumoylation. J Virol. 84, 2010: 11585-11589.
152. Mason, H. S., Lam, D. M., and Arntzen, C. J. Expression of
hepatitis B surface antigen in transgenic plants. Proc Natl Acad Sci.
89, 1992: 11745-11749.
153. Masterson, P.J., Stanley, M.A., Lewis, A.P. & Romanos, M.A. AC
terminal helicase domain of the human papillomavirus E1 protein
182
binds E2 and the DNA polymerase alpha-primase p68 subunit. J.
Virol. 72, 1998: 7407–7419.
154. McLean CS, Sterling JS, Mowat J, Nash AA, Stanley MA. Delayed-
type hypersensitivity response to the human papillomavirus type 16
E7 protein in a mouse model. J Gen Virol. 74, 1993: 239-245.
155. Meyers, C., Frattini, M.G., Hudson, J.B., and Laimins, L.A.
Biosynthesis of human papillomavirus from a continuous cell line
upon epithelial differentiation. Science. 257, 1992: 971–973.
156. Meyers, C., and Laimins Milich, D. R. Genetic and molecular basis
for T- and B-cell recognition of hepatitis B viral antigens. Immunol
Rev. 99, 1987: 71-103.
157. Moscicki AB, Ellenberg JH, Farhat S, Xu J. Persistence of human
papillomavirus infection in HIV- infected and –uninfected adolescent
girls: risk factors and differences, by phylogenetic type. J Infect Dis.
190, 2004: 37-45.
158. Muller, M., Zhou, J., Reed, T.D., Rittmuller, C., Burger, A.,
Gabelsberger, J., Braspenning, J., and Gissmann, L. Chimeric
papillomavirus-like particles. Virology. 234, 1997: 93–111.
183
159. Muñoz N, Castellsagué X, de González AB, Gissmann L. HPV in
the etiology of human cancer. Vaccine. 24 Suppl 3, 2006: S1-S10.
160. Nakagawa, M., Viscidi, R., Deshmukh, I., Costa, M.D., Palefsky,
J.M., Farhat, S., and Moscicki, A.B. Time course of humoral and cell-
mediated immune responses to human papillomavirus type 16 in
infected women. Clin Diagn Lab Immunol. 9, 2002: 877–882.
161. Nardelli-Haefliger D, Roden RB, Benyacoub J, Sahli R,
Kraehenbuhl JP, Schiller JT, Lachat P, Potts A, De Grandi P. Human
papillomavirus type 16 virus-like particles expressed in attenuated
Salmonella typhimurium elicit mucosal and systemic neutralizing
antibodies in mice. Infect Immun. 65, 1997: 3328-3336.
162. Nardelli-Haefliger, D., Lurati, F., Wirthner, D., Spertini, F.,
Schiller, J.T., Lowy, D.R., Ponci, F., and De Grandi, P. Immune
responses induced by lower airway mucosal immunisation with a
human papillomavirus type 16 virus-like particle vaccine. Vaccine.
23, 2005: 3634–3641.
163. Nasseri, M. & Wettstein, F.O. Differences exist between viral
transcripts in cottontail rabbit papillomavirus-induced benign and
malignant tumors as well as non-virus-producing and virus-
producing tumors. J Virol. 51, 1984: 706–712
184
164. Nelson, L. M., Rose, R. C., and Moroianu, J. Nuclear import
strategies of high risk HPV16 L1 major capsid protein. J Biol Chem.
277, 2002: 23958–23964.
165. Nicholls, P.K., Doorbar, J., Moore, R.A., Peh, W., Anderson, D.M.,
and Stanley, M.A. Detection of viral DNA and E4 protein in basal
keratinocytes of experimental canine oral papillomavirus lesions.
Virology. 284, 2001: 82–98.
166. Nonnenmacher, B., Hubbert, N.L., Kirnbauer, R., Shah, K.V.,
Munoz, N., Bosch, F.X., De Sanjose, S., Viscidi, R., Lowy, D.R., and
Schiller, J.T. Serologic response to human papillomavirus type 16
(HPV-16) virus-like particles in HPV-16 DNA-positive invasive cervical
cancer and cervical intraepithelial neoplasia grade III patients and
controls from Colombia and Spain. J Infect Dis. 172, 1995: 19–24.
167. O Connor, M., Chan, S. Y., Bernard, H. U. Transcription factor
binding sites in the long control region of genital HPVs. The Human
Papillomaviruses Compendium On Line (http://hpv-
web.lanl.gov/stdgen/virus/hpv/compendium/htdocs/), 1995: III-21
III-40.
185
168. Oh, S.T., Longworth, M.S., and Laimins, L.A. Roles of the E6 and
E7 proteins in the life cycle of low-risk human papillomavirus type
11. J Virol. 78, 2004b: 2620–2626.
169. Okoye, A., Cordano, P., Taylor, E.R., Morgan, I.M., Everett, R. &
Campo, M.S. Human papillomavirus 16 L2 inhibits the
transcriptional activation function, but not the DNA replication
function, of HPV-16 E2. Virus Res. 108, 2005: 1–14.
170. Okun, M. M., Day, P. M., Greenstone, H. L., Booy, F. P., Lowy, D.
R., Schiller, J. T., and Roden, R. B. L1 interaction domains of
papillomavirus l2 necessary for viral genome encapsidation. J. Virol.
75, 2001: 4332-4342.
171. Padmanabhan S, Amin T, Sampat B, Cook-Deegan R,
Chandrasekharan S. Intellectual property, technology transfer and
manufacture of low-cost HPV vaccines in India. Nat Biotechnol. 28,
2010: 671–678.
172. Paintsil, J., Muller, M., Picken, M., Gissmann, L., and Zhou, J.
Carboxyl terminus of bovine papillomavirus type-1 L1 protein is not
required for capsid formation. Virology. 223, 1996: 238–244.
173. Palker, T.J., Monteiro, J.M., Martin, M.M., Kakareka, C., Smith,
J.F., Cook, J.C., Joyce, J.G., and Jansen, K.U. Antibody, cytokine
186
and cytotoxic T lymphocyte responses in chimpanzees immunized
with human papillomavirus virus-like particles. Vaccine. 19, 2001:
3733–3743.
174. Park, R.B., and Androphy, E.J. Genetic analysis of high-risk e6 in
episomal maintenance of human papillomavirus genomes in primary
human keratinocytes. J Virol. 76, 2002: 11359–11364.
175. Parkin DM, Almonte M, Bruni L, Clifford G, Curado MP, Piñeros M.
Burden and trends of type-specific human papillomavirus infections
and related diseases in the Latin america and Caribbean region.
Vaccine. 26, Suppl 11, 2008: L1-15.
176. Pascoe, R.R., Knottenbelt, D.C.. Manual of equine dermatology.
London WB Saunders. 1999: 244- 250.
177. Pastrana, D.V., Gambhira, R., Buck, C.B., Pang, Y.Y., Thompson,
C.D., Culp, T.D., Christensen, N.D., Lowy, D.R., Schiller, J.T., and
Roden, R.B. Cross neutralization of cutaneous and mucosal
Papillomavirus types with anti-sera to the amino terminus of L2.
Virology. 337, 2005: 365–372.
178. Patel MC, Patkar KK, Basu A, Mohandas KM , Mukhopadhyaya R.
Production of immunogenic human papillomavirus-16 major capsid
187
protein derived virus like particles. Ind J Med Res. 130, 2009: 213-
218.
179. Peacock, J.W., Chung, S., Bristow, R.G., Hill, R.P., and Benchimol,
S. The p53-mediated G(1) checkpoint is retained in tumorigenic rat
embryo fibroblast clones transformed by the human papillomavirus
type 16 E7 gene and EJ-ras. Mol Cell Biol. 15, 1995: 1446–1454.
180. Peto J, Gilham C, Fletcher O, Matthews FE. The cervical cancer
epidemic that screening has prevented in the UK. Lancet. 364, 2006:
249-256.
181. Pim, D., Collins, M., and Banks, L. Human papillomavirus type 16
E5 gene stimulates the transforming activity of the epidermal growth
factor receptor. Oncogene. 7, 1992: 27-32.
182. Plummer, M. and Franceschi, S. Strategies for HPV prevention.
Virus Res. 89, 2002: 285-293.
183. Ressing, M. E., van Driel, W. J., Brandt, R. M., Kenter, G. G., de
Jong, J. H., Bauknecht, T., Fleuren, G. J., Hoogerhout, P., Offringa,
R., Sette, A., Celis, E., Grey, H., Trimbos, B. J., Kast, W. M., and
Melief, C. J. Detection of T helper responses, but not of human
papillomavirus-specific cytotoxic T lymphocyte responses, after
188
peptide vaccination of patients with cervical carcinoma. J
Immunother. 23, 2000: 255-266.
184. Rintala MA, Grénman SE, Puranen MH, Isolauri E, Ekblad U,
Kero PO, Syrjänen SM. Transmission of high-risk human
papillomavirus (HPV) between parents and infant: a prospective
study of HPV in families in Finland. J Clin Microbiol. 43, 2005: 376-
381.
185. Roberts, S., Ashmole, I., Johnson, G. D., Kreider, J. W., and
Gallimore, P. H. Cutaneous and mucosal human papillomavirus E4
proteins form intermediate filament-like structures in epithelial cells.
Virology. 197, 1993: 176-187.
186. Roberts, J.N., Buck, C.B., Thompson, C.D., Kines, R. and
Bernardo, M. Genital transmission of HPV in a mouse model is
potentiated by nonoxynol-9 and inhibited by carrageenan. Nat. Med.
13, 2007: 857–861.
187. Roberts, J. N., Kines, R. C., Katki, H. A., Lowy, D. R., Schiller, J. T.
Effect of Pap Smear Collection and Carrageenan on Cervicovaginal
Human Papillomavirus-16 Infection in a Rhesus Macaque Model. J
Natl Cancer Inst. 103, 2011: 737 -743.
189
188. Rockley, P.F., and Tyring, S.K. Interferons alpha, beta and gamma
therapy of anogenital human papillomavirus infections. Pharmacol
Ther. 65, 1995: 265–287.
189. Roden, R. B., Armstrong, A., Haderer, P., Christensen, N. D.,
Hubbert, N. L., Lowy, D. R., Schiller, J. T., and Kirnbauer, R.
Characterization of a human papillomavirus type 16 variant
dependent neutralizing epitope. J Virol. 71, 1997: 6247-6252.
190. Roden, R. B., Yutzy, W. H., Fallon, R., Inglis, S., Lowy, D. R., and
Schiller, J. T. Minor capsid protein of human genital
papillomaviruses contains subdominant, cross-neutralizing epitopes.
Virology. 270, 2000: 254-257.
191. Rohlfs, M., Winkenbach, S., Meyer, S., Rupp, T., and Durst, M.
Viral transcription in human keratinocyte cell lines immortalized by
human papillomavirus type-16. Virology. 183, 1991: 331–342.
192. Rose, R. C., Bonnez, W., Reichman, R. C., and Garcea, R. L.
Expression of human papillomavirus type 11 L1 protein in insect
cells: in vivo and in vitro assembly of virus like particles. J Virol. 67,
1993: 1936-1944.
193. Rudolf, M. P., Man, S., Melief, C. J., Sette, A., and Kast, W. M.
Human T-cell responses to HLA-A-restricted high binding affinity
190
peptides of human papillomavirus type 18 proteins E6 and E7. Clin.
Cancer Res. 7, 2001: S788-S795.
194. Sachs AB, Sarnow P, Hentze MW. Starting at the beginning, middle
and end: translation initiation in eukaryotes. Cell. 89, 1997: 831-
838.
195. Salunke, D.M., Caspar, D.L.D., and Garcea, R.L. Self-assembly of
purified polyomavirus capsid protein VP1. Cell 46, 1986: 895–904.
196. Sandhu KS, Pandey S, Maiti S, Pillai B. GACCO: Genetic algorithm
simulation for codon optimization. In Silico Biol. 8, 2008: 187-192.
197. Sankaranarayanan, R., Wesley, R., Somanathan, T., Dhakad, N.,
Shyamalakumary, B., Amma, N.S., Parkin, D.M. & Nair, M.K. Visual
inspection of the uterine cervix after the application of acetic acid in
the detection of cervical carcinoma and its precursors. Cancer. 83,
1998: 2150–2156.
198. Sankaranarayanan R, Budukh A, Rajkumar R. Effective screening
programs for cervical cancer in low- and middle income developing
countries. Bull World Health Organ. 79, 2001: 954-962.
199. Sankaranarayanan R.Overview of cervical cancer in the developing
world. FIGO 26th Annual Report on the Results of Treatment in
191
Gynecological Cancer. Int J Gynaecol Obstet. 95 Suppl 1, 2006: S205-
S210.
200. Sankaranarayanan R, Esmy PO, Rajkumar R, Muwonge R,
Swaminathan R, Shanthakumari S. Effect of visual screening on
cervical cancer incidence and mortality in Tamil Nadu, India: a
cluster-randomized trial. Lancet. 370, 2007: 398-406.
201. Sankaranarayanan R, Bhatla N, Gravitt PE, Basu P, Esmy PO,
Ashrafunnessa KS, Ariyaratne Y, Shah A, Nene BM. Human
papillomavirus infection and cervical cancer prevention in India,
Bangladesh, Sri Lanka and Nepal. Vaccine. 26 Suppl 12, 2008: S43-
S52.
202. Sankaranarayanan R. HPV Vaccination: the promise & problems.
Ind J Med Res. 130, 2009: 322-326.
203. Sapp, M., Fligge, C., Petzak, I., Harris, J.R., and Streeck, R.E.
Papillomavirus assembly requires trimerization of the major capsid
protein by disulfides between two highly conserved cysteines. J Virol.
72, 1998: 6186–6189.
204. Sasagawa T, Tani M, Basha W, Rose RC, Tohda H, Giga-Hama Y. A
human papillomavirus type 16 vaccine by oral delivery of L1 protein.
Virus Res. 110, 2005: 81–90.
192
205. Schirmbeck, R., Deml, L., Melber, K., Wolf, H., Wagner, R., and
Reimann, J. Priming of class I-restricted cytotoxic T lymphocytes by
vaccination with recombinant protein antigens. Vaccine. 13, 1995:
857-865.
206. Schiffman M, Castle PE. The promise of global cervical-cancer
prevention. N Engl J Med. 353, 2005: 2101-2104.
207. Schiller, J. T. and Lowy, D. R. Papillomavirus-like particles and
HPV vaccine development. Semin. Cancer Biol. 7, 1996: 373-382.
208. Schiller, J. T. Papillomavirus-like particle vaccines for cervical
cancer. Mol Med Today. 5, 1999: 209-215.
209. Schiller JT, Davies P. Delivering on the promise: HPV vaccines and
cervical cancer. Nat Rev Microbiol. 2, 2004: 343-347.
210. Schiller JT, Castellsagué X, Villa LL, Hildesheim A. An update of
prophylactic human papillomavirus L1 virus-like particle vaccine
clinical trial results. Vaccine. 26 Suppl 10, 2008: K53-K61.
211. Seedorf, K., Krammer, G., Durst, M., Suhai, S., and Rowekamp, W.
G. Human papillomavirus type 16 DNA sequence. Virology. 145,
1985: 181-185.
193
212. Sherman ME, Wang SS, Wheeler CM, Rich L, Gravitt PE, Tarone R,
Schiffman M. Determinants of human papillomavirus load among
women with histological cervical intraepithelial neoplasia 3:
dominant impact of surrounding low-grade lesions. Cancer Epidemiol
Biomarkers Prev. 12, 2003: 1038-1044.
213. Sinclair KA, Woods CR, Kirse DJ, Sinal SH. Anogenital and
respiratory tract human papillomavirus infections among children:
age, gender, and potential transmission through sexual abuse.
Pediatrics. 116, 2005: 815-825.
214. Slavinsky, J., III, Kissinger, P., Burger, L., Boley, A., DiCarlo, R.P.,
and Hagensee, M.E. Sero epidemiology of low and high oncogenic risk
types of human papillomavirus in a predominantly male cohort of
STD clinic patients. Int J STD AIDS. 12, 2001: 516–523.
215. Snijders PJ, Hogewoning CJ, Hesselink AT, Berkhof J, Voorhorst
FJ, Bleeker MC, Meijer CJ. Determination of viral load thresholds in
cervical scrapings to rule out CIN 3 in HPV 16, 18, 31 and 33-
positive women with normal cytology. Int J Cancer. 119, 2006: 1102-
1107.
216. Sowjanya AP, Jain M, Poli UR. Prevalence and distribution of high-
risk human papillomavirus (HPV) types in invasive squamous cell
194
carcinoma of the cervix and in normal women in Andhra Pradesh,
India. BMC Infect Dis. 5, 2005: 116-122.
217. Sreekrishna K, Brankamp RG, Kropp KE, Blankenship DT, Tsay
JT, Smith PL, Wierschke JD, Subramaniam A, Birkenberger LA.
Strategies for optimal synthesis and secretion of heterologous
proteins in the methylotrophic yeast Pichia pastoris. Gene. 190,
1997: 55-62.
218. Stellato, G., Paavonen, J., Nieminen, P., Hibma, M., Vilja, P., and
Lehtinen. M. Diagnostic phase antibody response to the human
papillomavirus type 16 E2 protein is associated with successful
treatment of genital HPV lesions with systemic interferon alpha-2b.
Clin. Diagn. Virol. 7, 1997: 167–172.
219. Steller, M. Cervical cancer vaccines: progress and prospects. J Soc
Gynecol Investig. 9, 2002: 254-264.
220. Sterling, J. C., Skepper, J. N., and Stanley, M. A. Immunoelectron
microscopical localization of human papillomavirus type 16 L1 and
E4 proteins in cervical keratinocytes cultured in vivo. J Invest
Dermatol. 100, 1993: 154-158.
195
221. Stoppler, M.C., Straight, S.W., Tsao, G., Schlegel, R. & McCance,
D.J. The E5 gene of HPV-16 enhances keratinocyte immortalization
by full-length DNA. Virology. 223, 1996: 251–254.
222. Stubenrauch, F., and Laimins, L.A. Human papillomavirus life
cycle: active and latent phases. Sem. Cancer Biol. 9, 1999: 379–386.
223. Stunkel, W., Huang, Z., Tan, S.H., O’Connor, M.J., nd Bernard, H.-
U. Nuclear matrix attachment regions of human papillomavirus type
16 repress or activate the E6 promoter, depending on the physical
state of the viral DNA. J Virol. 74, 2000: 2489–2501.
224. Sudbery, P. E. The expression of recombinant proteins in yeasts.
Curr Opin Biotechnol. 7, 1996: 517-524.
225. Suzich, J.A., Ghim, S., Palmer-Hill, F.J., White, W.I., Tamura, J.K.,
Bell, J., Newsome, J.A., Jenson, A.B., and Schlegel, R. Systemic
immunization with papillomavirus L1 protein completely prevents the
development of viral mucosal papillomas. Proc. Natl. Acad. Sci. USA .
92, 1995: 11553–11557.
226. Svare, E.I., Kjaer, S.K., Nonnenmacher, B., Worm, A.M., Moi, H.,
Christensen, R.B., van den Brule, A.J., Walboomers, J.M., Meijer,
C.J., Hubbert, N.L., Lowy, D.R., and Schiller, J.T. Seroreactivity to
196
human papillomavirus type 16 virus-like particles is lower in high-
risk men than in high-risk women. J Infect Dis. 176, 1997: 876–883.
227. Tenti P, Zappatore R, Migliora P, Spinillo A, Belloni C, Carnevali L.
Perinatal transmission of human papillomavirus from gravidas with
latent infections. Obstet Gynecol. 93, 1999: 475-479.
228. Thomas, J.T., Hubert, W.G., Ruesch, M.N., and Laimins, L.A.
Human papillomavirus type 31 oncoproteins E6 and E7 are required
for the maintenance of episomes during the viral life cycle in normal
human keratinocytes. Proc. Natl. Acad. Sci. USA. 96, 1999: 8449–
8454.
229. Titolo, S., Brault, K., Majewski, J., White, P.W. & Archambault, J.
Characterization of the minimal DNA binding domain of the human
papillomavirus e1 helicase: Fluorescence anisotropy studies and
characterization of a dimerization-defective mutant protein. J Virol.
77, 2003: 5178–5191.
230. Ustav, M., and Stenlund, A. Transient replication of BPV-1
requires two viral polypeptides encoded by the E1 and E2 open
reading frames. EMBO J. 10, 1991: 449–457.
197
231. Valle, G.F. & Banks, L. The human papillomavirus (HPV)-6 and
HPV-16 E5 proteins cooperate with HPV-16 E7 in the transformation
of primary rodent cells. J gen. Virol. 76, 1995: 1239–1245.
232. van der Burg, S. H., Kwappenberg, K. M., O'Neill, T., Brandt, R. M.,
Melief, C. J., Hickling, J. K., and Offringa, R. Pre-clinical safety and
efficacy of TA-CIN, a recombinant HPV16 L2E6E7 fusion protein
vaccine, in homologous and heterologous prime-boost regimens.
Vaccine. 19, 2001: 3652-3660.
233. Van Doornum, G.J., Prins, M., Pronk, L., Coutinho, R.A., and
Dillner, J. A prospective study of antibody responses to defined
epitopes of human papillomavirus (HPV) type 16 in relationship to
genital and ano rectal presence of HPV DNA. Clin Diagn Lab Immunol.
1, 1994: 633–639.
234. van Kuppeveld, F. J. M., de Jong, A., Dijkman, H. B. P. M., Andino,
R., and Melchers, W. J. G. Studies towards the potential of poliovirus
as a vector for the expression of HPV 16 virus-like-particles. FEMS
Immunology and Medical Microbiology. 34, 2002: 201-208.
235. Van Regenmortel, M.H.V., Fauquet, C.M., Bishop, D.H.L.,
Carstens, E.B., Estes, M.K., Lemon, S.M., Maniloff, J., Mayo, M.A.,
McGeoch, D.J., Pringle, C.R., Wickner, R.B. Virus Taxonomy: The
198
Classification and Nomenclature of viruses. The Seventh Reports of
the International Committee on Taxonomy of Viruses. Academic
press, San Diego, 2000.
236. Varsani A, Williamson AL, Rose RC, Jaffer M, Rybicki EP.
Expression of human papillomavirus type 16 major capsid protein in
transgenic Nicotiana tabacum cv. Xanthi. Arch Virol. 148, 2003: 1771-
1786.
237. Villa, L.L., Costa, R.L., Petta, C.A., Andrade, R.P., Ault, K.A.,
Giuliano, A.R., Wheeler, C.M., Koutsky, L.A., Malm, C., Lehtinen, M.,
Skjeldestad, F.E., Olsson, S.E., Steinwall, M., Brown, D.R., Kurman,
R.J., Ronnett, B.M., Stoler, M.H., Ferenczy, A., Harper, D.M., Tamms,
G.M., Yu, J., Lupinacci, L., Railkar, R., Taddeo, F.J., Jansen K.U.,
Esser, M.T., Sings, H.L., Saah, A.J., and Barr, E. Prophylactic
quadrivalent human papillomavirus (types 6, 11, 16, and 18) L1
virus-like particle vaccine in young women: a randomized double-
blind placebo-controlled multicentre phase II efficacy trial. Lancet
Oncol. 6, 2005: 271–278.
238. Villa LL. Prophylactic HPV vaccines: reducing the burden of HPV-
related diseases. Vaccine. 24 Suppl 1, 2006: S23-S28.
199
239. Volpers, C., Schirmacher, P., Streeck, R. E., and Sapp, M.
Assembly of the major and the minor capsid protein of human
papillomavirus type 33 into virus-like particles and tubular
structures in insect cells. Virology. 200, 1994: 504-512.
240. Wank, R. and Thomssen, C. High risk of squamous cell carcinoma
of the cervix for women with HLA-DQw3. Nature. 352, 1991: 723–
725.
241. Walboomers, J. M., Jacobs, M. V., Manos, M. M., Bosch, F. X.,
Kummer, J. A., Shah, K. V., Snijders, P. J., Peto, J., Meijer, C. J.,
and Munoz, N. Human papillomavirus is a necessary cause of
invasive cervical cancer worldwide. J Pathol. 189, 1999: 12-19.
242. Wang, Z., Christensen, N., Schiller, J. T., and Dillner, J. A
monoclonal antibody against intact human papillomavirus type 16
capsids blocks the serological reactivity of most human sera. J Gen
Virol. 78, 1997: 2209-2215.
243. Wang, Z.H., Kjellberg, L., Abdalla, H., Wiklund, F., Eklund, C.,
Knekt, P., Lehtinen, M., Kallings, I., Lenner, P., Hallmans, G.,
Mahlck, C.G., Wadell, G., Schiller, J., and Dillner, J. Type specificity
and significance of different isotypes of serum antibodies to human
papillomavirus capsids. J Infect Dis. 181, 2000: 456–462.
200
244. White, A.E., Livanos, E.M., and Tlsty, T.D. Differential disruption
of genomic integrity and cell cycle regulation in normal human
fibroblasts by the HPV onco proteins. Genes Dev. 8, 1994: 666–677.
245. White, P.W., Pelletier, A., Brault, K., Titolo, S., Welchner, E.,
Thauvette, L., Fazekas, M., Cordingley, M.G. & Archambault, J.
Characterization of recombinant HPV6 and 11 E1 helicases. Effect of
ATP on the interaction of E1 with E2 and mapping of a minimal
helicase domain. J biol Chem. 276, 2001: 22426–22438.
246. WHO/ICO Information Centre on HPV and Cervical Cancer (HPV
Information Centre). Human Papillomavirus and Related Cancers in
India. Summary Report, 2010: 6-15 (www.who.int./hpvcentre).
247. Wideroff, L., Schiffman, M.H., Nonnenmacher, B., Hubbert, N.,
Kirnbauer, R., Greer, C.E., Lowy, D., Lorincz, A.T., Manos, M.M.,
Glass, A.G., Scott, D.R., Sherman, M.E., Buckland, J., Lowy, D., and
Schiller, J. Evaluation of sero reactivity to human papillomavirus
type 16 virus-like particles in an incident case-control study of
cervical neoplasia. J Infect Dis. 172, 1995: 1425–1430.
248. Wikstrom, A., Van Doornum, G.J., Quint, W.G., Schiller, J.T., and
Dillner, J. Identification of human papillomavirus sero conversions. J
Gen Virol. 76, 1995b: 529–539.
201
249. Wilson, V. G., West, M., Woytek, K., and Rangasamy, D.
Papillomavirus E1 proteins: form, function, and features. Virus
Genes. 24, 2002: 275-290.
250. Winer RL, Kiviat NB, Hughes JP. Development and duration of
human papillomavirus lesions, after initial infection. J Infect Dis.
191, 2005: 731-738.
251. Woodworth, C.D., Lichti, U., Simpson, S., Evans, C.H., and
DiPaolo, J.A. Leukoregulin and gamma-interferon inhibit human
papillomavirus type 16 gene transcription in human papillomavirus-
immortalized human cervical cells. Cancer Res. 52, 1992: 456–463.
252. Wu, X., Xiao, W., and Brandsma, J.L. Papilloma formation by
cottontail rabbit papillomavirus requires E1 and E2 regulatory genes
in addition to E6 and E7 transforming genes. J Virol. 68, 1994: 6097–
6102.
253. Wurm, F. and Bernard, A. Large-scale transient expression in
mammalian cells for recombinant protein production. Curr Opin
Biotechnol. 10, 1999: 156-159.
254. Yang, R., Murillo, F.M., Delannoy, M.J., Blosser, R.L., Yutzy,
W.H.T., Uematsu, S., Takeda, K., Akira, S., Viscidi, R.P., and Roden,
202
R.B. B lymphocyte activation by human papillomavirus-like particles
directly induces Ig class switch recombination via TLR4-MyD88. J
Immunol. 174, 2005: 7912–7919.
255. Yim, T. J., Tang, S., and Andino, R. Poliovirus recombinants
expressing hepatitis B virus antigens elicited a humoral immune
response in susceptible mice. Virology. 218, 1996: 61-70.
256. Yufang Hu, Roya Zandi, Adriana Anavitarte, Charles M. Knobler,
William M. Gelbart. Packaging of a Polymer by a Viral Capsid: The
Interplay between Polymer Length and Capsid Size. Biophys J. 94,
2008: 1428–1436.
257. Yutsudo, M., Okamoto, Y., and Hakura, A. Functional dissociation
of transforming genes of human papillomavirus type 16. Virology.
166, 1988: 594–597.
258. Zinkernagel, R.M. On natural and artificial vaccinations. Ann Rev
Immunol. 21, 2003: 515–546.
259. Zhang, B., Spandau, D.F. & Roman, A. E5 protein of human
papillomavirus type 16 protects human foreskin keratinocytes from
UV B-irradiation-induced apoptosis. J Virol. 76, 2002: 220–231.
203
260. Zou, N., Lin, B.Y., Duan, F., Lee, K.-Y., Jin, G., Guan, R., Yao, G.,
Lefkowitz, E.J., Broker, T.R. & Chow, L.T. The hinge of the human
papillomavirus type 11 E2 protein contains major determinants for
nuclear localization and nuclear matrix association. J Virol. 74, 2000:
3761–3770.
261. Zhou, J., Doorbar, J., Sun, X. Y., Crawford, L. V., McLean, C. S.,
and Frazer, I. H. Identification of the nuclear localization signal of
human papilloma virus type 16 L1 protein. Virology. 185, 1991a:
625-632.
262. Zhou J, Sun XY, Stenzel DJ, Frazer IH. Expression of vaccinia
recombinant HPV 16 L1 and L2 ORF proteins in epithelial cells is
sufficient for assembly of HPV virion-like particles. Virology. 185,
1991b: 251-257.
263. Zhou, J., Stenzel, D.J., Sun, X.Y., and Frazer, I.H. Synthesis and
assembly of infectious bovine papilloma virus particles in vitro. J Gen
Virol. 74, 1993: 763–768.
264. zur Hausen H. Papillomavirus infections--a major cause of human
cancers. Biochem Biophys Acta. 1288, 1996: F55-F78.
265. zur Hausen, H. Papillomaviruses and cancer: From basic studies to
clinical application. Nat Rev Cancer. 2, 2002: 342–350.